Genetic markers indicate which non-small-cell lung cancer patients may benefit from adjuvant therapy
Wednesday, December 15, 2010 (Last Updated: 12/16/2010)
WEDNESDAY, Dec. 15 (HealthDay News) -- Using a tool based on six gene markers, oncologists may be better able to identify stage I non-small-cell lung cancer (NSCLC) patients more at risk for relapse who might benefit from adjuvant therapy, according to a study presented at the 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology, held from Dec. 9 to 11.
Jimmy Ruiz, M.D., of the Wake Forest University School of Medicine in Winston-Salem, N.C., and colleagues analyzed the microarray expression profiles of stage I NSCLC tumors from more than 300 stage IA/IB patients to construct and validate a tool for determining prognosis based on genetic information.
From a training cohort of 120 subjects, the team identified a six-gene prognostic classifier that could stratify patients into three groups -- high-, intermediate-, and low-risk -- with significantly different relapse rates. They validated the six-gene stage I NSCLC classifier ("S1N" classifier) in a cohort of 179 subjects and found the results for high-risk subjects to be similar to those in the test group, estimating a more than 80 percent relapse rate within five years. However, the low- and intermediate-risk groups' survival times did not remain significantly different.
"The six-gene S1N classifier identifies a high-risk group of stage I patients for whom surgery alone is insufficient. High-risk patients identified by the S1N classifier may benefit from the chemotherapy offered to later stage patients," the authors write.
Hematology & Oncology
Copyright © 2010 HealthDay. All rights reserved.
October 08, 2012
November 25, 2015